Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carbonyl reductase [NADPH] 1 (CBR1) is a cytosolic, monomeric NADPH-dependent oxidoreductase belonging to the short-chain dehydrogenase/reductase (SDR) superfamily. It is widely distributed in human tissues, with high expression in the liver, epidermis, and gastrointestinal tract, where it plays a critical role in the metabolism of a broad range of endogenous and xenobiotic carbonyl compounds, including quinones, prostaglandins, and lipid aldehydes. CBR1 is highly clinically relevant due to its role in metabolizing anthracycline chemotherapeutics, such as doxorubicin and daunorubicin, into their corresponding secondary alcohol metabolites (e.g., doxorubicinol), which are less effective as anticancer agents and significantly contribute to chronic cardiotoxicity. Consequently, CBR1 is a major therapeutic target for co-administration strategies; inhibiting CBR1 can prevent the formation of cardiotoxic metabolites, thereby mitigating anthracycline-induced cardiotoxicity and overcoming drug resistance in various cancers. Additionally, CBR1 plays a protective role against oxidative stress by detoxifying reactive lipid aldehydes, meaning its inhibition must be carefully managed to avoid cellular damage.
Inhibition of carbonyl reductase [NADPH] 1 prevents the reduction of anthracyclines (such as doxorubicin and daunorubicin) to their cardiotoxic alcohol metabolites (doxorubicinol and daunorubicinol), thereby reducing cardiotoxicity and enhancing chemotherapeutic efficacy.
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carbonyl reductase [NADPH] 1 (CBR1).